CASI - CASI Pharmaceuticals Reports Positive Interim Phase 1 Data For BI-1206

2024-03-05 07:49:55 ET

DENVER, Colo., Mar 05, 2024 ( 247marketnews.com )- CASI Pharmaceuticals, Inc. (NASDAQ: CASI ) and BioInvent International AB (Nasdaq Stockholm: BINV) announced, this morning, initial efficacy data for BI-1206, a first-in-class fully human monoclonal antibody (mAb) that targets Fc?RIIB, in combination with rituximab in patients with relapsed/refractory (R/R) indolent Non-Hodgkin’s Lymphoma (iNHL) in the ongoing development program in China.

The Phase 1 dose-escalation study showed impressive signs of clinical efficacy, with 4 partial responses (PR) and 1 complete response (CR) out of 8 evaluable patients.

CASI is trading at $7.06, up $2.01 (+39.80%), on 2.33M shares.

Dr. Wei-Wu He, CEO of CASI, said “These initial BI-1206 data showed promising response for patients with difficult-to-treat disease. The data are especially notable as they demonstrated strong and durable responses at lower dose levels. We believe these results represent important steps toward validating BI-1206 as a potential treatment as well as de-risk our plan for future development.”

Dr. Martin Welschof, CEO of BioInvent commented, “We are encouraged by the promising new interim Phase 1 data reported today by our partner, CASI. BI-1206 is being developed to re-establish the clinical efficacy of cancer therapies such as rituximab by addressing fundamental resistance mechanisms to cancer treatments. The clinical efficacy results reported today, including a long-lasting complete response, reinforce previously reported data. We continue to be enthusiastic about the development of BI-1206 in NHL and look forward to reporting data from additional studies in the first half of 2024.”

The post CASI Pharmaceuticals Reports Positive Interim Phase 1 Data For BI-1206 appeared first on 24/7 MarketNews .

For further details see: